- Home
- BIAF vs GSIW Comparison
BIAF vs GSIW Comparison
Compare BIAF & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- GSIW
- Stock Information
- Founded
- BIAF 2014
- GSIW 2016
- Country
- BIAF United States
- GSIW Hong Kong
- Employees
- BIAF N/A
- GSIW N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GSIW
- Sector
- BIAF Health Care
- GSIW
- Exchange
- BIAF Nasdaq
- GSIW Nasdaq
- Market Cap
- BIAF 7.1M
- GSIW 8.1M
- IPO Year
- BIAF 2022
- GSIW 2023
- Fundamental
- Price
- BIAF $0.24
- GSIW $0.10
- Analyst Decision
- BIAF Hold
- GSIW
- Analyst Count
- BIAF 1
- GSIW 0
- Target Price
- BIAF N/A
- GSIW N/A
- AVG Volume (30 Days)
- BIAF 468.1K
- GSIW 10.6M
- Earning Date
- BIAF 08-14-2025
- GSIW 01-01-0001
- Dividend Yield
- BIAF N/A
- GSIW N/A
- EPS Growth
- BIAF N/A
- GSIW N/A
- EPS
- BIAF N/A
- GSIW N/A
- Revenue
- BIAF $7,681,059.00
- GSIW $5,368,221.00
- Revenue This Year
- BIAF N/A
- GSIW N/A
- Revenue Next Year
- BIAF $20.00
- GSIW N/A
- P/E Ratio
- BIAF N/A
- GSIW N/A
- Revenue Growth
- BIAF 4.99
- GSIW 283.23
- 52 Week Low
- BIAF $0.16
- GSIW $0.09
- 52 Week High
- BIAF $2.26
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- BIAF 39.54
- GSIW 21.69
- Support Level
- BIAF $0.24
- GSIW $0.09
- Resistance Level
- BIAF $0.26
- GSIW $0.10
- Average True Range (ATR)
- BIAF 0.02
- GSIW 0.01
- MACD
- BIAF 0.00
- GSIW 0.03
- Stochastic Oscillator
- BIAF 17.02
- GSIW 31.18
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.